On the stock market since 2026, it operates in the world of health and science. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly below the class average.
The price is looking for direction — no strong breakout, no collapse.
Growth: Sales growth trails the sector average.
Business Quality: Profit power and business quality trail similar companies in the sector.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: Right now the product sells for less than it costs to make; every sale deepens the loss.
The stock trades 41% below its peak. The market has trimmed its expectations for the company.
Sales run at $6.5M a year. A small number, but proof the product has real buyers.
There is $226.8M in the vault; even if every debt were paid off, $215.2M would remain.
The average analyst price target is $35.33 — 86% above today’s price.
A loss of $63.7M against $6.5M in annual sales.
The growth engine is running at low revs right now. Report-card grade: 15/100.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 30/100.
On our five-subject report card, AKTS sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: AKTS is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (52/100) says the stock isn’t cheap.